LAG3 and B-cell chronic lymphocytic leukemia: Relatlimab, the first LAG-3 mAb, has shown promising anti-tumor effects in chronic lymphocytic leukemia (CLL) by restoring the immune activities of NK cells and T cells (74) (Figure 2).